Profile
Sector:
HealthcareCountry:
United StatesIPO:
15 February 2022Website:
http://sunshinebiopharma.comNext earnings report:
20 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 102 min agoDividend
Analysts recommendations
Institutional Ownership
SBFM Latest News
FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023.
FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix®.
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties Research was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection.
FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61).
Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Monday after the pharmaceutical company received a delisting notice from the Nasdaq Exchange. That delisting notice notes that shares of SBFM stock have been trading for less than the $1 minimum bid price for too long.
Sunshine Biopharma (NASDAQ: SBFM ) stock is falling on Friday after the pharmaceutical company revealed details of a private offering for its shares. Sunshine Biopharma has agreed to sell 5,952,381 units and pre-funded units at a purchase price of 84 cents per unit to a single healthcare-focused institutional investor.
Canadian biotech company Sunshine Biopharma (NASDAQ: SBFM ) is among the leaders in today's rather volatile session. Currently, shares of SBFM stock are up more than 60% after the company announced what appears to be incredible earnings.
What type of business is Sunshine Biopharma?
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
What sector is Sunshine Biopharma in?
Sunshine Biopharma is in the Healthcare sector
What industry is Sunshine Biopharma in?
Sunshine Biopharma is in the Drug Manufacturers - Specialty & Generic industry
What country is Sunshine Biopharma from?
Sunshine Biopharma is headquartered in United States
When did Sunshine Biopharma go public?
Sunshine Biopharma initial public offering (IPO) was on 15 February 2022
What is Sunshine Biopharma website?
https://sunshinebiopharma.com
Is Sunshine Biopharma in the S&P 500?
No, Sunshine Biopharma is not included in the S&P 500 index
Is Sunshine Biopharma in the NASDAQ 100?
No, Sunshine Biopharma is not included in the NASDAQ 100 index
Is Sunshine Biopharma in the Dow Jones?
No, Sunshine Biopharma is not included in the Dow Jones index
When was Sunshine Biopharma the previous earnings report?
No data
When does Sunshine Biopharma earnings report?
The next expected earnings date for Sunshine Biopharma is 20 May 2025